There is no published human trial studying concurrent administration of two injectable GLP-1 agonists, so the combined drug-interaction and adverse-event profile is unknown
10.1016/j.stemcr.2015.04.004 17 Dinkova-KostovaA
No mega-tablets, just real results.
Concomitant administration of the drug with drugs that induce hypocarnitinemia due to increased loss of renal carnitine (valproic acid, prodrugs containing pivalic acid, cephalosporins, cisplatin, carboplatin and ifosfamide) can reduce the availability of L-carnitine
Inhibiting system Xc reduces GSH production, thereby diminishing the activity of GPX4 and leading to ROS accumulation, ultimately driving ferroptosis in CRC cells [61, 69-72]
Retatrutide has been evaluated in registered clinical studies, but those programs concern the developers investigational drug and controlled trial material